A new tumor category has therefore emerged due to new treatment options, while at present, treatment decision-making is dominated by the HR status [12], and traditional anti-HER2 therapies such as trastuzumab have not shown any significant improvements in survival in HER2-low-positive breast cancer patients [13]. Here, ERBB2 is linked to neoplasm.